
Human Microbiome Industry Research Report 2024
Description
Human Microbiome Industry Research Report 2024
Summary
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
According to APO Research, The global Human Microbiome market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Human Microbiome is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Human Microbiome is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Human Microbiome is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Human Microbiome include Vedanta, Seres Therapeutics, Second Genome, Rebiotix, ActoGeniX, Enterome BioScience, AvidBiotics, 4D Pharma Research Ltd and Enterologics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Microbiome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Microbiome.
The Human Microbiome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Microbiome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Human Microbiome segment by Type
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Others
Human Microbiome Segment by Application
Treatment
Diagnosis
Human Microbiome Segment by Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Microbiome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Microbiome and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Microbiome.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Human Microbiome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
126 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Human Microbiome by Type
- 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
- 2.2.2 Gastrointestinal Tract Human Micobiome
- 2.2.3 Urogenital Tract Human Micobiome
- 2.2.4 Others
- 2.3 Human Microbiome by Application
- 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
- 2.3.2 Treatment
- 2.3.3 Diagnosis
- 2.4 Assumptions and Limitations
- 3 Human Microbiome Breakdown Data by Type
- 3.1 Global Human Microbiome Historic Market Size by Type (2019-2024)
- 3.2 Global Human Microbiome Forecasted Market Size by Type (2025-2030)
- 4 Human Microbiome Breakdown Data by Application
- 4.1 Global Human Microbiome Historic Market Size by Application (2019-2024)
- 4.2 Global Human Microbiome Forecasted Market Size by Application (2019-2024)
- 5 Global Growth Trends
- 5.1 Global Human Microbiome Market Perspective (2019-2030)
- 5.2 Global Human Microbiome Growth Trends by Region
- 5.2.1 Global Human Microbiome Market Size by Region: 2019 VS 2023 VS 2030
- 5.2.2 Human Microbiome Historic Market Size by Region (2019-2024)
- 5.2.3 Human Microbiome Forecasted Market Size by Region (2025-2030)
- 5.3 Human Microbiome Market Dynamics
- 5.3.1 Human Microbiome Industry Trends
- 5.3.2 Human Microbiome Market Drivers
- 5.3.3 Human Microbiome Market Challenges
- 5.3.4 Human Microbiome Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Human Microbiome Players by Revenue
- 6.1.1 Global Top Human Microbiome Players by Revenue (2019-2024)
- 6.1.2 Global Human Microbiome Revenue Market Share by Players (2019-2024)
- 6.2 Global Human Microbiome Industry Players Ranking, 2022 VS 2023 VS 2024
- 6.3 Global Key Players of Human Microbiome Head office and Area Served
- 6.4 Global Human Microbiome Players, Product Type & Application
- 6.5 Global Human Microbiome Players, Date of Enter into This Industry
- 6.6 Global Human Microbiome Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Human Microbiome Market Size (2019-2030)
- 7.2 North America Human Microbiome Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 7.3 North America Human Microbiome Market Size by Country (2019-2024)
- 7.4 North America Human Microbiome Market Size by Country (2025-2030)
- 7.5 United States
- 7.6 Canada
- 8 Europe
- 8.1 Europe Human Microbiome Market Size (2019-2030)
- 8.2 Europe Human Microbiome Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 8.3 Europe Human Microbiome Market Size by Country (2019-2024)
- 8.4 Europe Human Microbiome Market Size by Country (2025-2030)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Russia
- 8.10 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Human Microbiome Market Size (2019-2030)
- 9.2 Asia-Pacific Human Microbiome Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 9.3 Asia-Pacific Human Microbiome Market Size by Country (2019-2024)
- 9.4 Asia-Pacific Human Microbiome Market Size by Country (2025-2030)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 Southeast Asia
- 9.9 India
- 9.10 Australia
- 10 Latin America
- 10.1 Latin America Human Microbiome Market Size (2019-2030)
- 10.2 Latin America Human Microbiome Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 10.3 Latin America Human Microbiome Market Size by Country (2019-2024)
- 10.4 Latin America Human Microbiome Market Size by Country (2025-2030)
- 10.5 Mexico
- 10.6 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Human Microbiome Market Size (2019-2030)
- 11.2 Middle East & Africa Human Microbiome Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 11.3 Middle East & Africa Human Microbiome Market Size by Country (2019-2024)
- 11.4 Middle East & Africa Human Microbiome Market Size by Country (2025-2030)
- 11.5 Turkey
- 11.6 Saudi Arabia
- 11.7 UAE
- 12 Players Profiled
- 12.1 Vedanta
- 12.1.1 Vedanta Company Information
- 12.1.2 Vedanta Business Overview
- 12.1.3 Vedanta Revenue in Human Microbiome Business (2019-2024)
- 12.1.4 Vedanta Human Microbiome Product Portfolio
- 12.1.5 Vedanta Recent Developments
- 12.2 Seres Therapeutics
- 12.2.1 Seres Therapeutics Company Information
- 12.2.2 Seres Therapeutics Business Overview
- 12.2.3 Seres Therapeutics Revenue in Human Microbiome Business (2019-2024)
- 12.2.4 Seres Therapeutics Human Microbiome Product Portfolio
- 12.2.5 Seres Therapeutics Recent Developments
- 12.3 Second Genome
- 12.3.1 Second Genome Company Information
- 12.3.2 Second Genome Business Overview
- 12.3.3 Second Genome Revenue in Human Microbiome Business (2019-2024)
- 12.3.4 Second Genome Human Microbiome Product Portfolio
- 12.3.5 Second Genome Recent Developments
- 12.4 Rebiotix
- 12.4.1 Rebiotix Company Information
- 12.4.2 Rebiotix Business Overview
- 12.4.3 Rebiotix Revenue in Human Microbiome Business (2019-2024)
- 12.4.4 Rebiotix Human Microbiome Product Portfolio
- 12.4.5 Rebiotix Recent Developments
- 12.5 ActoGeniX
- 12.5.1 ActoGeniX Company Information
- 12.5.2 ActoGeniX Business Overview
- 12.5.3 ActoGeniX Revenue in Human Microbiome Business (2019-2024)
- 12.5.4 ActoGeniX Human Microbiome Product Portfolio
- 12.5.5 ActoGeniX Recent Developments
- 12.6 Enterome BioScience
- 12.6.1 Enterome BioScience Company Information
- 12.6.2 Enterome BioScience Business Overview
- 12.6.3 Enterome BioScience Revenue in Human Microbiome Business (2019-2024)
- 12.6.4 Enterome BioScience Human Microbiome Product Portfolio
- 12.6.5 Enterome BioScience Recent Developments
- 12.7 AvidBiotics
- 12.7.1 AvidBiotics Company Information
- 12.7.2 AvidBiotics Business Overview
- 12.7.3 AvidBiotics Revenue in Human Microbiome Business (2019-2024)
- 12.7.4 AvidBiotics Human Microbiome Product Portfolio
- 12.7.5 AvidBiotics Recent Developments
- 12.8 4D Pharma Research Ltd
- 12.8.1 4D Pharma Research Ltd Company Information
- 12.8.2 4D Pharma Research Ltd Business Overview
- 12.8.3 4D Pharma Research Ltd Revenue in Human Microbiome Business (2019-2024)
- 12.8.4 4D Pharma Research Ltd Human Microbiome Product Portfolio
- 12.8.5 4D Pharma Research Ltd Recent Developments
- 12.9 Enterologics
- 12.9.1 Enterologics Company Information
- 12.9.2 Enterologics Business Overview
- 12.9.3 Enterologics Revenue in Human Microbiome Business (2019-2024)
- 12.9.4 Enterologics Human Microbiome Product Portfolio
- 12.9.5 Enterologics Recent Developments
- 12.10 Metabogen
- 12.10.1 Metabogen Company Information
- 12.10.2 Metabogen Business Overview
- 12.10.3 Metabogen Revenue in Human Microbiome Business (2019-2024)
- 12.10.4 Metabogen Human Microbiome Product Portfolio
- 12.10.5 Metabogen Recent Developments
- 12.11 Metabiomics
- 12.11.1 Metabiomics Company Information
- 12.11.2 Metabiomics Business Overview
- 12.11.3 Metabiomics Revenue in Human Microbiome Business (2019-2024)
- 12.11.4 Metabiomics Human Microbiome Product Portfolio
- 12.11.5 Metabiomics Recent Developments
- 12.12 Ritter Pharmaceuticals
- 12.12.1 Ritter Pharmaceuticals Company Information
- 12.12.2 Ritter Pharmaceuticals Business Overview
- 12.12.3 Ritter Pharmaceuticals Revenue in Human Microbiome Business (2019-2024)
- 12.12.4 Ritter Pharmaceuticals Human Microbiome Product Portfolio
- 12.12.5 Ritter Pharmaceuticals Recent Developments
- 12.13 Osel
- 12.13.1 Osel Company Information
- 12.13.2 Osel Business Overview
- 12.13.3 Osel Revenue in Human Microbiome Business (2019-2024)
- 12.13.4 Osel Human Microbiome Product Portfolio
- 12.13.5 Osel Recent Developments
- 12.14 Symberix
- 12.14.1 Symberix Company Information
- 12.14.2 Symberix Business Overview
- 12.14.3 Symberix Revenue in Human Microbiome Business (2019-2024)
- 12.14.4 Symberix Human Microbiome Product Portfolio
- 12.14.5 Symberix Recent Developments
- 12.15 Miomics
- 12.15.1 Miomics Company Information
- 12.15.2 Miomics Business Overview
- 12.15.3 Miomics Revenue in Human Microbiome Business (2019-2024)
- 12.15.4 Miomics Human Microbiome Product Portfolio
- 12.15.5 Miomics Recent Developments
- 12.16 Symbiotix Biotherapies
- 12.16.1 Symbiotix Biotherapies Company Information
- 12.16.2 Symbiotix Biotherapies Business Overview
- 12.16.3 Symbiotix Biotherapies Revenue in Human Microbiome Business (2019-2024)
- 12.16.4 Symbiotix Biotherapies Human Microbiome Product Portfolio
- 12.16.5 Symbiotix Biotherapies Recent Developments
- 12.17 MicroBiome Therapeutics LLC
- 12.17.1 MicroBiome Therapeutics LLC Company Information
- 12.17.2 MicroBiome Therapeutics LLC Business Overview
- 12.17.3 MicroBiome Therapeutics LLC Revenue in Human Microbiome Business (2019-2024)
- 12.17.4 MicroBiome Therapeutics LLC Human Microbiome Product Portfolio
- 12.17.5 MicroBiome Therapeutics LLC Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.